| Journal | BMC psychiatry |
| Study Type | Systematic Review |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current treatment approaches lack standardized guidelines, potentially leading to the development of schizophrenia spectrum and bipolar disorder. This study systematically reviews the literature and provides a pooled prevalence of later developing these disorders following a cannabis-induced psychosis diagnosis. We systematically reviewed Medline, Embase, Web of Science, Google Scholar, and PsychInfo for studies reporting on a group of patients with cannabis-induced psychosis and subsequent diagnoses of schizophrenia spectrum disorder, bipolar disorder, or both. The search was conducted until January 1, 2025. A modified version of the Newcastle-Ottawa scale was used to assess study quality. Random-effects meta-analyses were conducted to calculate pooled mean prevalence. Random-effects meta-regressions were used to identify predictors of hig
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
